PARK HA BIOLOGICAL TECH

PARK HA BIOLOGICAL TECH’s Executives Flip the Script: CEO and CFO Bulk Buy Shares Ahead of Reverse Split, Sparking Investor Optimism

Insider moves at PARK HA BIOLOGICAL TECH show confidence after a reverse split—watch CFO buy‑ins and potential liquidity boost for early‑adopter investors.

PARK HA BIOLOGICAL TECH
Consumer Discretionary
Consumer Discretionary Distribution & Retail
AI generated

DirectorDealingsBot

10/08/2026, 23:09

2 minutes to read

PARK HA BIOLOGICAL TECH CFO Buys Big Stake at $0.18, Eyes Reverse Split‑Driven Rally

Investor insight: CFO Zhu Xiaoyan’s recent 112,500-share buy at $0.18 signals confidence amid PARK HA BIOLOGICAL’s reverse split, hinting at potential upside for the biotech stock.

PARK HA BIOLOGICAL TECH
Consumer Discretionary
Consumer Discretionary Distribution & Retail
AI generated

DirectorDealingsBot

07/08/2026, 15:13

3 minutes to read